Back to search results

Symptom Monitoring for Advanced Chronic Kidney Disease

This study is testing a new way to monitor symptoms for people with advanced chronic kidney disease (CKD, stages 4 and 5). It uses an electronic survey called IPOS-Renal to track symptoms monthly. The goal is to see how well this system works in routine care and if it helps improve your health-related quality of life. You might be able to join if you are an adult with advanced CKD, can read and write English, and are under the care of a nephrologist at Mass General Brigham. The study is currently unclear on its recruitment status.

Study design
This is a single-center, open-label, randomized pilot study with 70 participants. You would be randomly assigned to either use the electronic symptom survey or receive standard care.
What's involved
If in the intervention group, you would complete the electronic IPOS-Renal survey monthly for 12 months. Your responses would be shared with your doctors to help manage your symptoms.
Compensation
Not stated in the trial record.
Follow-up
The study will track symptom survey completion rates over 12 months of active participation.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07186218

Symptom Monitoring With Supported Feedback in Advanced Chronic Kidney Disease

Recruiting
NAAges 18+InterventionalSupportive care
Massachusetts General Hospital
~70 participants
Updated 2026-06-22 on ClinicalTrials.gov
What's tested:Electronic patient-reported outcome measure (ePROM) for symptom monitoring

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Reach (Implementation); Screen-eligibility
Measured over Baseline
+5 more outcomes measured

Conditions

Chronic Kidney Disease (Stages 4 and 5)
Health Related Quality of Life

Explore related trials

Chronic Kidney Disease

NCT07186218

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Mass General Brigham

    Boston, Massachusettsstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Kendra Wulczyn, MD, MPH
[email protected]
617-726-5050
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adults (age ≥ 18 years)
Advanced CKD, defined as at least two measurements of creatinine-based or cystatin C-based eGFR ≤ 30 mL/min/1.73m2 separated by at least 90 days in the preceding 12 months
Able to provide consent to participate in the study
Able to read and write in English
Under the care of a nephrologist at a Mass General Brigham nephrology clinic

Exclusion

Terminal illness likely to lead to death within 6 months of participation
Patients receiving dialysis treatment at the time of enrollment or scheduled to start dialysis therapy in the next 4 weeks
Patients scheduled to receive a kidney transplant in the next 6 months
Patients having their initial clinic visit (i.e., new to the clinic)
Cognitive deficits that would preclude understanding of consent form and/or questionnaires

What this trial measures

  • Reach (Implementation); Screen-eligibilityBaseline

    Percent of screen-eligible patients from pool of patients with advanced CKD screened for eligibility.

  • Reach (Implementation); Rate of consentingBaseline

    Percent of screen-eligible patients approached to participate in study who provide consent to participate

  • Feasibility (Implementation); symptom survey completion rateDuration of active 12-month study participation

    Rate of completion of electronic symptom questionnaires by participants

  • Feasibility (Implementation); Symptom documentationDuration of active 12-month study participation

    Frequency of symptom documentation by clinicians in the clinical visit note for participants

  • Feasibility (Implementation); Interviews3-12 months of participation

    Clinician and patient participant answers to interview questions regarding the extent to which the ePROM intervention fits within the ambulatory nephrology setting.

  • Acceptability (Implementation); Interviews3-12 months of participation

    Clinician and patient participant answers to interview questions regarding satisfaction with and acceptability of the ePROM intervention.